FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 303:1323-1329 December 4, 1980 Number 23 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Within three weeks of definitive surgical intervention, 467 patients with histologically proved malignant glioma were randomized to receive one of four treatment regimens: semustine (MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus radiotherapy. We analyzed the data for the total randomized population and for the 358 patients in whom the initial protocol specifications were met (the valid study group). Observed toxicity included acceptable skin reactions secondary to radiotherapy and reversible leukopenia and thrombocytopenia due to chemotherapy. Radiotherapy used alone or in combination with a nitrosourea significantly improved survival in comparison with semustine alone. The group receiving carmustine plus radiotherapy had the best survival, but the difference in survival between the groups receiving carmustine plus radiotherapy and semustine plus radiotherapy was not statistically significant. The combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significiant at the 0.05 level. This study suggests that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.

This article has been cited by other articles:

• Karpel-Massler, G., Schmidt, U., Unterberg, A., Halatsch, M.-E. (2009). Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?. Mol Cancer Res 7: 1000-1012 [Abstract] [Full Text]  
• Blumenthal, D. T., Won, M., Mehta, M. P., Curran, W. J., Souhami, L., Michalski, J. M., Rogers, C. L., Corn, B. W. (2009). Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. JCO 27: 733-739 [Abstract] [Full Text]  
• Wakabayashi, T., Kayama, T., Nishikawa, R., Takahashi, H., Yoshimine, T., Hashimoto, N., Aoki, T., Kurisu, K., Natsume, A., Ogura, M., Yoshida, J. (2008). A Multicenter Phase I Trial of Interferon-{beta} and Temozolomide Combination Therapy for High-grade Gliomas (INTEGRA Study). Jpn J Clin Oncol 38: 715-718 [Abstract] [Full Text]  
• Phuphanich, S., Carson, K. A., Grossman, S. A., Lesser, G., Olson, J., Mikkelsen, T., Desideri, S., Fisher, J. D., for the New Approaches to Brain Tumor Therapy (NAB, (2008). Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol Duke 10: 617-623 [Abstract] [Full Text]  
• Liang, X.-J., Choi, Y., Sackett, D. L., Park, J. K. (2008). Nitrosoureas Inhibit the Stathmin-Mediated Migration and Invasion of Malignant Glioma Cells. Cancer Res. 68: 5267-5272 [Abstract] [Full Text]  
• Lustig, R., Mikkelsen, T., Lesser, G., Grossman, S., Ye, X., Desideri, S., Fisher, J., Wright, J., the New Approaches to Brain Tumor Therapy CNS Cons, (2008). Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol Duke 10: 1004-1009 [Abstract] [Full Text]  
• Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., Chin, L., DePinho, R. A., Cavenee, W. K. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21: 2683-2710 [Abstract] [Full Text]  
• Yamini, B., Yu, X., Pytel, P., Galanopoulos, N., Rawlani, V., Veerapong, J., Bickenbach, K., Weichselbaum, R. R. (2007). Adenovirally Delivered Tumor Necrosis Factor-{alpha} Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy. Clin. Cancer Res. 13: 6217-6223 [Abstract] [Full Text]  
• Lally, B. E., Geiger, G. A., Kridel, S., Arcury-Quandt, A. E., Robbins, M. E., Kock, N. D., Wheeler, K., Peddi, P., Georgakilas, A., Kao, G. D., Koumenis, C. (2007). Identification and Biological Evaluation of a Novel and Potent Small Molecule Radiation Sensitizer via an Unbiased Screen of a Chemical Library. Cancer Res. 67: 8791-8799 [Abstract] [Full Text]  
• Martinez, R., Setien, F., Voelter, C., Casado, S., Quesada, M. P., Schackert, G., Esteller, M. (2007). CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 28: 1264-1268 [Abstract] [Full Text]  
• Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., Menei, P., Loiseau, H., Bernier, V., Honnorat, J., Barrie, M., Mokhtari, K., Mazeron, J.-J., Bissery, A., Delattre, J.-Y., the Association of French-Speaking Neuro-Oncologis, (2007). Radiotherapy for Glioblastoma in the Elderly. NEJM 356: 1527-1535 [Abstract] [Full Text]  
• Badruddoja, M. A., Penne, K., Desjardins, A., Reardon, D. A., Rich, J. N., Quinn, J. A., Sathornsumetee, S., Friedman, A. H., Bigner, D. D., Herndon, J. E. II, Cahill, A., Friedman, H. S., Vredenburgh, J. J. (2007). Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol Duke 9: 70-74 [Abstract] [Full Text]  
• Tome, W A, Howard, S P (2007). On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br. J. Radiol. 80: 32-37 [Abstract] [Full Text]  
• Limoli, C. L., Giedzinski, E., Baure, J., Doctrow, S. R., Rola, R., Fike, J. R. (2006). Using superoxide dismutase/catalase mimetics to manipulate the redox environment of neural precursor cells. Radiat Prot Dosimetry 122: 228-236 [Abstract] [Full Text]  
• Chakravarti, A., Erkkinen, M. G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M. R., Black, P. McL., Loeffler, J. S. (2006). Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clin. Cancer Res. 12: 4738-4746 [Abstract] [Full Text]  
• Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., Mehta, M., Curran, W. (2006). Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. JCO 24: 2707-2714 [Abstract] [Full Text]  
• Kneifel, S., Cordier, D., Good, S., Ionescu, M. C.S., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., Arnold, M., Mueller-Brand, J., Maecke, H. R., Reubi, J. C., Merlo, A. (2006). Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P.. Clin. Cancer Res. 12: 3843-3850 [Abstract] [Full Text]  
• Gilbert, M. R. (2006). New treatments for malignant gliomas: careful evaluation and cautious optimism required.. ANN INTERN MED 144: 371-373 [Full Text]  
• Reardon, D. A., Wen, P. Y. (2006). Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.. The Oncologist 11: 152-164 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., on behalf of the European Organisation for Researc, (2006). Changing paradigms--an update on the multidisciplinary management of malignant glioma.. The Oncologist 11: 165-180 [Abstract] [Full Text]  
• Carson-Walter, E. B., Hampton, J., Shue, E., Geynisman, D. M., Pillai, P. K., Sathanoori, R., Madden, S. L., Hamilton, R. L., Walter, K. A. (2005). Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis. Clin. Cancer Res. 11: 7643-7650 [Abstract] [Full Text]  
• Yuan, L., Choi, K., Khosla, C., Zheng, X., Higashikubo, R., Chicoine, M. R., Rich, K. M. (2005). Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Molecular Cancer Therapeutics 4: 1293-1302 [Abstract] [Full Text]  
• Cao, Y., Tsien, C. I., Shen, Z., Tatro, D. S., Ten Haken, R., Kessler, M. L., Chenevert, T. L., Lawrence, T. S. (2005). Use of Magnetic Resonance Imaging to Assess Blood-Brain/Blood-Glioma Barrier Opening During Conformal Radiotherapy. JCO 23: 4127-4136 [Abstract] [Full Text]  
• Pelloski, C. E., Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., Passe, S., Jenkins, R. B., Aldape, K. D. (2005). YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma. Clin. Cancer Res. 11: 3326-3334 [Abstract] [Full Text]  
• Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., Mirimanoff, R. O., the European Organisation for Research and Treatme, (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. NEJM 352: 987-996 [Abstract] [Full Text]  
• Tseng, S.-H., Chen, Y., Chang, C.-J., Tai, K.-F., Lin, S.-M., Hwang, L.-H. (2005). Induction of T-Cell Apoptosis in Rats by Genetically Engineered Glioma Cells Expressing Granulocyte-Macrophage Colony-Stimulating Factor and B7.1. Clin. Cancer Res. 11: 1639-1649 [Abstract] [Full Text]  
• Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., Loeffler, J. S. (2004). The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas. JCO 22: 1926-1933 [Abstract] [Full Text]  
• Tseng, S.-H., Lin, S.-M., Chen, J.-C., Su, Y.-H., Huang, H.-Y., Chen, C.-K., Lin, P.-Y., Chen, Y. (2004). Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats. Clin. Cancer Res. 10: 2190-2202 [Abstract] [Full Text]  
• Chua, S. L., Rosenthal, M. A., Wong, S. S., Ashley, D. M., Woods, A.-m., Dowling, A., Cher, L. M. (2004). Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol Duke 6: 38-43 [Abstract]  
• Brown, P. D., Wald, J. T., McDermott, M. W., Baumann, G. S., Cloughesy, T. F. (2003). Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma.. RadioGraphics 23: 1591-1611 [Full Text]  
• The Neuro-Oncology Working Group of the German Can, (2003). Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma. JCO 21: 3276-3284 [Abstract] [Full Text]  
• Grossman, S. A., O'Neill, A., Grunnet, M., Mehta, M., Pearlman, J. L., Wagner, H., Gilbert, M., Newton, H. B., Hellman, R. (2003). Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394. JCO 21: 1485-1491 [Abstract] [Full Text]  
• Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jaaskelainen, J., Ram, Z. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol Duke 5: 79-88 [Abstract]  
• van den Bent, M., Chinot, O.-L., Cairncross, J. G. (2003). Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol Duke 5: 128-138 [Abstract]  
• Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal, G., Faivre, S., Sicard, E., Germa, C., Rodier, J. M., Vernillet, L., Armand, J. P. (2003). Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14: 603-614 [Abstract] [Full Text]  
• Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., Loeffler, J. S. (2002). The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner. Cancer Res. 62: 4307-4315 [Abstract] [Full Text]  
• Stupp, R., Dietrich, P.-Y., Kraljevic, S. O., Pica, A., Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R., Porchet, F., Regli, L., de Tribolet, N., Mirimanoff, R. O., Leyvraz, S. (2002). Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. JCO 20: 1375-1382 [Abstract] [Full Text]  
• Chakravarti, A., Noll, E., Black, P. McL., Finkelstein, D. F., Finkelstein, D. M., Dyson, N. J., Loeffler, J. S. (2002). Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas. JCO 20: 1063-1068 [Abstract] [Full Text]  
• Adachi, Y., Lakka, S. S., Chandrasekar, N., Yanamandra, N., Gondi, C. S., Mohanam, S., Dinh, D. H., Olivero, W. C., Gujrati, M., Tamiya, T., Ohmoto, T., Kouraklis, G., Aggarwal, B., Rao, J. S. (2001). Down-regulation of Integrin alpha vbeta 3 Expression and Integrin-mediated Signaling in Glioma Cells by Adenovirus-mediated Transfer of Antisense Urokinase-type Plasminogen Activator Receptor (uPAR) and Sense p16 Genes. J. Biol. Chem. 276: 47171-47177 [Abstract] [Full Text]  
• Gururangan, S., Cokgor, I., Rich, J. N., Edwards, S., Affronti, M. L., Quinn, J. A., Herndon, J. E. II, Provenzale, J. M., McLendon, R. E., Tourt-Uhlig, S., Sampson, J. H., Stafford-Fox, V., Zaknoen, S., Early, M., Friedman, A. H., Friedman, H. S. (2001). Phase I study of GliadelTM wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol Duke 3: 246-250 [Abstract]  
• Jones, G., Machado, J. Jr., Tolnay, M., Merlo, A. (2001). PTEN-independent Induction of Caspase-mediated Cell Death and Reduced Invasion by the Focal Adhesion Targeting Domain (FAT) in Human Astrocytic Brain Tumors Which Highly Express Focal Adhesion Kinase (FAK). Cancer Res. 61: 5688-5691 [Abstract] [Full Text]  
• Bethune, C. R., Geyer, R. J., Spence, A. M., Ho, R. J. Y. (2001). Lipid Association Improves the Therapeutic Index of Lomustine [1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea] to Suppress 36B-10 Tumor Growth in Rats. Cancer Res. 61: 3669-3674 [Abstract] [Full Text]  
• Yang, J., Yang, J.-M., Iannone, M., Shih, W. J., Lin, Y., Hait, W. N. (2001). Disruption of the EF-2 Kinase/Hsp90 Protein Complex: A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin. Cancer Res. 61: 4010-4016 [Abstract] [Full Text]  
• Yin, J.-H., Yang, D.-I, Chou, H., Thompson, E. M., Xu, J., Hsu, C. Y. (2001). Inducible Nitric Oxide Synthase Neutralizes Carbamoylating Potential of 1,3-Bis(2-chloroethyl)-1-nitrosourea in C6 Glioma Cells. J. Pharmacol. Exp. Ther. 297: 308-315 [Abstract] [Full Text]  
• Geng, L., Donnelly, E., McMahon, G., Lin, P. C., Sierra-Rivera, E., Oshinka, H., Hallahan, D. E. (2001). Inhibition of Vascular Endothelial Growth Factor Receptor Signaling Leads to Reversal of Tumor Resistance to Radiotherapy. Cancer Res. 61: 2413-2419 [Abstract] [Full Text]  
• Fisher, B. J., Scott, C., Macdonald, D. R., Coughlin, C., Curran, W. J. (2001). Phase I Study of Topotecan Plus Cranial Radiation for Glioblastoma Multiforme: Results of Radiation Therapy Oncology Group Trial 9507. JCO 19: 1111-1117 [Abstract] [Full Text]  
• Rosenthal, M. A., Kavar, B., Hill, J. S., Morgan, D. J., Nation, R. L., Stylli, S. S., Basser, R. L., Uren, S., Geldard, H., Green, M. D., Kahl, S. B., Kaye, A. H. (2001). Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin. JCO 19: 519-524 [Abstract] [Full Text]  
• Doolittle, N. D., Anderson, C. P., Bleyer, W. A., Cairncross, J. G., Cloughesy, T., Eck, S. L., Guastadisegni, P., Hall, W. A., Muldoon, L. L., Patel, S. J., Peereboom, D., Siegal, T., Neuwelt, E. A., for the Blood-Brain Barrier Disruption Consortium, (2001). Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro Oncol Duke 3: 46-54 [Abstract]  
• Nutt, C. L., Noble, M., Chambers, A. F., Cairncross, J. G. (2000). Differential Expression of Drug Resistance Genes and Chemosensitivity in Glial Cell Lineages Correlate with Differential Response of Oligodendrogliomas and Astrocytomas to Chemotherapy. Cancer Res. 60: 4812-4818 [Abstract] [Full Text]  
• Plautz, G. E., Miller, D. W., Barnett, G. H., Stevens, G. H. J., Maffett, S., Kim, J., Cohen, P. A., Shu, S. (2000). T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas. Clin. Cancer Res. 6: 2209-2218 [Abstract] [Full Text]  
• Del Rowe, J., Scott, C., Werner-Wasik, M., Bahary, J. P., Curran, W. J., Urtasun, R. C., Fisher, B. (2000). Single-Arm, Open-Label Phase II Study of Intravenously Administered Tirapazamine and Radiation Therapy for Glioblastoma Multiforme. JCO 18: 1254-1259 [Abstract] [Full Text]  
• Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., Yung, W.K. A. (1999). Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. JCO 17: 2572-2572 [Abstract] [Full Text]  
• Clarke, K., Basser, R. L., Underhill, C., Mitchell, P., Bartlett, J., Cher, L., Findlay, M., Dalley, D., Pell, M., Byrne, M., Geldard, H., Hill, J. S., Maher, D., Fox, R. M., Green, M. D., Kaye, A. H. (1999). KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma. JCO 17: 2579-2579 [Abstract] [Full Text]  
• Harada, H., Nakagawa, K., Iwata, S., Saito, M., Kumon, Y., Sakaki, S., Sato, K., Hamada, K. (1999). Restoration of Wild-Type p16 Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Gliomas. Cancer Res. 59: 3783-3789 [Abstract] [Full Text]  
• Huhn, S. L., Mohapatra, G., Bollen, A., Lamborn, K., Prados, M. D., Feuerstein, B. G. (1999). Chromosomal Abnormalities in Glioblastoma Multiforme by Comparative Genomic Hybridization: Correlation with Radiation Treatment Outcome. Clin. Cancer Res. 5: 1435-1443 [Abstract] [Full Text]  
• Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M., McLendon, R. E., Bigner, D. D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G. L., Miller, L. L. (1999). Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma. JCO 17: 1516-1516 [Abstract] [Full Text]  
• Merlo, A., Hausmann, O., Wasner, M., Steiner, P., Otte, A., Jermann, E., Freitag, P., Reubi, J.-C., Muller-Brand, J., Gratzl, O., Macke, H. R. (1999). Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90Y-Labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A Pilot Study in Human Gliomas. Clin. Cancer Res. 5: 1025-1033 [Abstract] [Full Text]  
• Ross, B. D., Zhao, Y.-J., Neal, E. R., Stegman, L. D., Ercolani, M., Ben-Yoseph, O., Chenevert, T. L. (1998). Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: An MRI study. Proc. Natl. Acad. Sci. USA 95: 7012-7017 [Abstract] [Full Text]  
• Gregor, A., Cull, A. (1996). Radiotherapy for malignant glioma. BMJ 313: 1500-1501 [Full Text]  
• Davies, E., Clarke, C., Hopkins, A. (1996). Malignant cerebral glioma--I: Survival, disability, and morbidity after radiotherapy. BMJ 313: 1507-1512 [Abstract] [Full Text]  
• Martuza, R., Malick, A, Markert, J., Ruffner, K., Coen, D. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856 [Abstract]  
• Mahaley, M. S. Jr (1986). Clinical Investigative Neuro-oncology. Arch Intern Med 146: 374-377 [Abstract]  
• Baker, S. R., Makuch, R. W., Wolf, G. T. (1981). Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response. Arch Otolaryngol Head Neck Surg 107: 683-689 [Abstract]  
• NEUWELT, E. A., DIEHL, J. T., VU, L. H., HILL, S. A., MICHAEL, A. J., FRENKEL, E. P. (1981). Monitoring of Methotrexate Delivery in Patients with Malignant Brain Tumors After Osmotic Blood-Brain Barrier Disruption. ANN INTERN MED 94: 449-454 [Abstract]